A detailed history of Geode Capital Management, LLC transactions in Immatics N.V. stock. As of the latest transaction made, Geode Capital Management, LLC holds 110,007 shares of IMTX stock, worth $834,953. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,007
Previous 110,217 0.19%
Holding current value
$834,953
Previous $1.28 Million 1.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.93 - $12.92 $2,295 - $2,713
-210 Reduced 0.19%
110,007 $1.26 Million
Q2 2024

Aug 09, 2024

BUY
$9.78 - $13.49 $217,614 - $300,165
22,251 Added 25.3%
110,217 $1.28 Million
Q1 2024

May 13, 2024

BUY
$10.23 - $12.94 $37,431 - $47,347
3,659 Added 4.34%
87,966 $924,000
Q4 2023

Feb 13, 2024

SELL
$7.36 - $10.89 $9,428 - $13,950
-1,281 Reduced 1.5%
84,307 $887,000
Q3 2023

Nov 13, 2023

BUY
$11.01 - $12.62 $326,776 - $374,561
29,680 Added 53.09%
85,588 $991,000
Q2 2023

Aug 11, 2023

BUY
$5.92 - $12.72 $133,490 - $286,823
22,549 Added 67.59%
55,908 $645,000
Q2 2022

Aug 12, 2022

SELL
$6.0 - $9.37 $102,858 - $160,629
-17,143 Reduced 33.95%
33,359 $290,000
Q1 2022

May 13, 2022

SELL
$6.64 - $12.85 $2,682 - $5,191
-404 Reduced 0.79%
50,502 $403,000
Q4 2021

Feb 11, 2022

BUY
$10.81 - $14.38 $15,760 - $20,966
1,458 Added 2.95%
50,906 $684,000
Q3 2021

Nov 12, 2021

BUY
$11.58 - $15.46 $36,534 - $48,776
3,155 Added 6.82%
49,448 $642,000
Q2 2021

Aug 13, 2021

BUY
$10.43 - $12.81 $14,904 - $18,305
1,429 Added 3.19%
46,293 $537,000
Q1 2021

May 12, 2021

BUY
$10.24 - $14.6 $117,811 - $167,973
11,505 Added 34.49%
44,864 $502,000
Q3 2020

Nov 13, 2020

BUY
$8.73 - $15.15 $291,224 - $505,388
33,359 New
33,359 $353,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $579M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.